Quest Diagnostics' Haystack MRD Test Gains Nationwide Approval with Key New York State Nod
DGX sits 20% above its 52-week low of $164.65.
Summary
Quest Diagnostics' Haystack MRD test, a circulating tumor DNA liquid biopsy for solid tumor monitoring, has secured approval from the New York State Department of Health. This critical regulatory clearance means the test is now authorized for patient use in all 50 U.S. states. The nationwide market access significantly expands the commercial opportunity for this oncology diagnostic, enabling broader adoption for earlier disease detection and recurrence monitoring.
At the time of this announcement, DGX was trading at $197.18 on NYSE in the Life Sciences sector, with a market capitalization of approximately $21.8B. The 52-week trading range was $164.65 to $213.50. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: dpa-AFX.